Nina Schwalbe began her career in health over 25 years ago in a refugee camp in Northern Thailand. Nina current currently leads a public health advisory service which provides policy and strategy guidance to governments, international organizations and foundations. Nina has served as the acting Associate Director of the Program Division and Chief of Health for UNICEF, implementing health-related programs in over 150 countries. In her time at UNICEF, she developed a new agency-wide strategy for health. Prior to UNICEF, Nina served on the executive team of Gavi, the vaccine alliance. As Managing Director for Policy and Performance, she led Gavi's work in strategic planning, policy development, market-shaping, performance management and monitoring and evaluation. She also developed Gavi's strategy, a key component of their successful advocacy and replenishment efforts. Before Gavi, Nina directed the policy department at the Global Alliance for Tuberculosis Drug Development, where she focused on product introduction and advocacy. Nina came to the TB Alliance from the Soros Foundations, where she had developed and directed their global public health program. Nina has also worked for the Population Council and AVSC International (now EngenderHealth) implementing programs and advocating with governments for adoption of new technologies. She has worked across Asia, Europe and Africa.
Honors & Awards
Areas of Expertise
E-health, Adolescent Health, Disparities / Inequalities in Health, Social Epidemiology, Global Health Diplomacy, Global Health, Immunization, Tuberculosis, Public Health Leadership and Management
Select Urban Health Activities
Select Global Activities
Global Partnerships : Nina served on the design team for the Global Financing Facility in Support of Every Woman Every Child and continues to advise a number of public-private partnerships including Gavi, the vaccine alliance and the Global Fund to Fight Aids, TB and Malaria.
Gavi, the vaccine alliance: Nina chairs Gavi's Evaluation Advisory Committee
Nguyen A, Schwalbe N. Apples and oranges? Can second generation vaccines become as low cost as generic medicines?. Vaccine. 2019;37(22):2910Ã¢â‚¬Â2914. doi:10.1016/j.vaccine.2019.04.016
Schwalbe N, Wahl B. Artificial intelligence and the future of global health. Lancet. 2020;395(10236):1579Ã¢â‚¬Â1586. doi:10.1016/S0140-6736(20)30226-9
Wahl B, Cossy-Gantner A, Germann S, Schwalbe N. Artificial intelligence (AI) and global health: how can AI contribute to health in resource-poor settings?BMJ Global Health 2018;3:e000798.
Brumana L, Arroyo A, Schwalbe NR, et al Maternal and child health services and an integrated, life-cycle approach to the prevention of non-communicable diseases BMJ Global Health 2017;2:e000295.
Nina Schwalbe, Ibrahim El Ziq. GAVI's Advance Market Commitment. The Lancet 2010, 375 (9715): 638-39.
Subhashani Chandrasekharan, Tahir Amin, Joice Kim, Elaine Furrer, Anna Carin Matterson Nina Schwalbe, Aurelia Nguyen. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers. Vaccine, 33 (2015) 6366-6370
Celina M Hanson, Eliane Furrer, Nina Schwalbe, Seth Berkley. Prediction of immunization performance. The Lancet, Vol 381, February 2, 2013.
Tania Cernuschi, Eliane Furrer, Nina Schwalbe, Andrew Jones, Ernst R Berndt & Susan McAdams. Advance market commitment for pneumococcal vaccines: putting theory into practice. Bulletin of the World Health Organization, 2011; 89:913-918; doi:10.2471/BLT.11.087700
Helen Saxenian, Santiago Cornejo, Kira Thorien, Robert Hecht, and Nina Schwalbe. An analysis of how the GAVI Alliance, low-income, and middle-income countries can share costs of new vaccines. Health Affairs, 2011 Jun, 30:6 (1-13).
William A. Wells, Niranjan Konduri, Cynthia Chen, David Lee, Heather R. Ignatius, Elizabeth Gardiner, and Nina R. Schwalbe. Tuberculosis regimen change in high- burden countries. International Journal of Tuberculosis and Lung Disease, 2011 Mar, 15(3): 425.